Share this article
Share this article
VANCOUVER, BC, June 28, 2021 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) ( BioVaxys or the Company ) is pleased to announce a non-brokered private placement (the Private Placement ) consisting of up to 9,090,909 units ( Units ) at a price of $0.22 per Unit for total gross proceeds of up to approximately $2,000,000. Each Unit consists of one common share (a Common Share ) and one whole Common Share purchase warrant (a Warrant ). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.50 for a period of 30 months.
All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. The Company may pay cash finder s fees on all or a portion of the Private Placement.
BioVaxys Technology : Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
DUBAI, June 10, 2021 - (ACN Newswire) - The 7th edition of the world-renowned flagship Global Blockchain Congress by Agora Group is taking place on June 21st and 22nd, 2021 in Dubai & co-hosted by TDeFi.